These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7645538

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients.
    Johnson CA, Wakeen M, Taylor CA, Zimmerman SW, Burkart J, Bhattacharya A, Kosorok MR.
    Perit Dial Int; 1999; 19(6):578-82. PubMed ID: 10641779
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF, End-Stage Renal Disease Core Indicators Work Group.
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA, Gimenez LF, Graber SE, Van Stone JC, Egrie JC, Okamoto DM.
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [Abstract] [Full Text] [Related]

  • 6. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [Abstract] [Full Text] [Related]

  • 7. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA.
    N Engl J Med; 1998 Aug 27; 339(9):578-83. PubMed ID: 9718376
    [Abstract] [Full Text] [Related]

  • 9. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 27; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul 27; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 27; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 12. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.
    Besarab A.
    Am J Kidney Dis; 1993 Aug 27; 22(2 Suppl 1):13-22. PubMed ID: 8352267
    [Abstract] [Full Text] [Related]

  • 13. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun 27; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study.
    Bren A, Kandus A, Varl J, Buturović J, Ponikvar R, Kveder R, Primozic S, Ivanovich P.
    Artif Organs; 2002 Feb 27; 26(2):91-7. PubMed ID: 11879235
    [Abstract] [Full Text] [Related]

  • 18. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD, Cooper B.
    Nephrology (Carlton); 2004 Aug 27; 9(4):223-8. PubMed ID: 15363054
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
    Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC.
    Clin Pharmacol Ther; 1998 Oct 27; 64(4):412-23. PubMed ID: 9797798
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.